Voyager Therapeutics adds proof its gene therapy for Parkinson's can work, shares soar
Voyager Therapeutics $VYGR says it’s turned an important corner in its development of a gene therapy that can play a major role in rescuing Parkinson’s patients from the inevitable decline associated with their response to levodopa.
The Cambridge, MA-based biotech has fleshed out its early-stage proof-of-concept data on VY-AADC01, offering new data that demonstrate a heightened efficacy for two higher doses of the gene therapy. Executives at Voyager tell me that they’re heartened to see a dose-dependent response in a key biomarker on their therapy’s impact, with improvements in hourly “on” times, a drop in “off” times and better quality of living scores from the 15 patients divided into three therapeutic cohorts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.